ASS1 and non-small cell lung carcinoma: ADIPemCis treatment induced a disease control rate of 85.7% (n = 18/21; 95% CI 63.7%–97%), and a partial response rate of 47.6% (n = 10/21, 95% CI 25.7%–70.2%; or n = 10/18 or 55.6% of evaluable patients), in a cohort of patients with non‐squamous NSCLC enriched by ASS1 loss, summarized in Figure 2C,D.